Blab Business
Corvus Pharmaceuticals Advances Soquelitinib to Phase 3 for Peripheral T-Cell Lymphoma While Expanding Atopic Dermatitis Trial
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) announced on October 10 2024 that it has launched a registrational Phase 3 study of its selective interleukin‑2‑inducible T‑cell kinase (ITK) inhibitor, soquelitinib (CPI‑818), in patients with relapsed or refractory peripheral T‑cell lymphoma (PTCL). The company also confirmed that a Phase 2, double‑blind, placebo‑controlled trial—named SIERRA1—will assess soquelitinib in adults with moderate‑to‑severe atopic dermatitis (AD). These two studies anchor the company’s core pipeline and are expected to deliver pivotal data in 2027.
The Phase 3 trial is the first registrational study of soquelitinib and is enrolling patients across the United States. According to a press release, the study will compare soquelitinib to standard of care in a randomized, controlled design and will evaluate overall response rate and progression‑free survival as primary endpoints. The trial follows an orphan drug designation granted by the U.S. Food and Drug Administration (FDA) in February 2024, a status that provides development incentives for treatments of rare diseases. An end‑of‑phase meeting with the FDA in early 2024 confirmed the company’s plans to initiate the Phase 3 study.
PTCL is a heterogeneous group of aggressive non‑Hodgkin lymphomas that arise from mature T‑cells. Current treatment options are limited and often involve multi‑agent chemotherapy or stem‑cell transplantation, with survival rates remaining low. The FDA’s orphan designation for soquelitinib reflects the disease’s rarity and the unmet medical need.
SIERRA1 is a Phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial that began enrollment in early 2026. The study will evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in adults with moderate‑to‑severe AD. The trial’s primary endpoint is the proportion of patients achieving a 75 % improvement in the Eczema Area and Severity Index (EASI‑75) at week 12. Topline results are expected in the third quarter of 2027.
Corvus’s financial position supports its clinical program. As of the October 2024 announcement, the company reported $215.2 million in cash and cash equivalents. This balance is projected to fund operations through the second quarter of 2028, according to the company’s financial statements, reducing the likelihood of near‑term equity dilution.
The company’s leadership has emphasized that soquelitinib remains its primary focus. In a statement accompanying the Phase 3 launch, executives noted that they are concentrating on patient enrollment and trial execution across both the oncology and dermatology indications. The company’s strategy is to deliver positive data in 2027, a milestone that analysts say could influence regulatory prospects and valuation.
In addition to the two clinical programs, Corvus maintains a broader pipeline that includes other investigational agents, but the company has not disclosed further details about those projects.
The Phase 3 PTCL trial is currently underway, with an interim futility analysis scheduled for the first quarter of 2027. The AD Phase 2 study will report topline data in Q3 2027. The company’s cash position provides a buffer through 2028, and no additional financing has been announced. Regulatory milestones—such as the interim futility review and the AD topline—will be key events for investors and stakeholders in the coming months.
Corvus’s progress illustrates the challenges of developing therapies for rare, high‑need indications and the importance of a robust clinical development plan supported by adequate financial resources.
The Phase 3 trial is the first registrational study of soquelitinib and is enrolling patients across the United States. According to a press release, the study will compare soquelitinib to standard of care in a randomized, controlled design and will evaluate overall response rate and progression‑free survival as primary endpoints. The trial follows an orphan drug designation granted by the U.S. Food and Drug Administration (FDA) in February 2024, a status that provides development incentives for treatments of rare diseases. An end‑of‑phase meeting with the FDA in early 2024 confirmed the company’s plans to initiate the Phase 3 study.
PTCL is a heterogeneous group of aggressive non‑Hodgkin lymphomas that arise from mature T‑cells. Current treatment options are limited and often involve multi‑agent chemotherapy or stem‑cell transplantation, with survival rates remaining low. The FDA’s orphan designation for soquelitinib reflects the disease’s rarity and the unmet medical need.
SIERRA1 is a Phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial that began enrollment in early 2026. The study will evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in adults with moderate‑to‑severe AD. The trial’s primary endpoint is the proportion of patients achieving a 75 % improvement in the Eczema Area and Severity Index (EASI‑75) at week 12. Topline results are expected in the third quarter of 2027.
Corvus’s financial position supports its clinical program. As of the October 2024 announcement, the company reported $215.2 million in cash and cash equivalents. This balance is projected to fund operations through the second quarter of 2028, according to the company’s financial statements, reducing the likelihood of near‑term equity dilution.
The company’s leadership has emphasized that soquelitinib remains its primary focus. In a statement accompanying the Phase 3 launch, executives noted that they are concentrating on patient enrollment and trial execution across both the oncology and dermatology indications. The company’s strategy is to deliver positive data in 2027, a milestone that analysts say could influence regulatory prospects and valuation.
In addition to the two clinical programs, Corvus maintains a broader pipeline that includes other investigational agents, but the company has not disclosed further details about those projects.
The Phase 3 PTCL trial is currently underway, with an interim futility analysis scheduled for the first quarter of 2027. The AD Phase 2 study will report topline data in Q3 2027. The company’s cash position provides a buffer through 2028, and no additional financing has been announced. Regulatory milestones—such as the interim futility review and the AD topline—will be key events for investors and stakeholders in the coming months.
Corvus’s progress illustrates the challenges of developing therapies for rare, high‑need indications and the importance of a robust clinical development plan supported by adequate financial resources.
